Rapid Point Of Care COVID-19 Antigen Test Market Overview and Analysis
The Global Rapid Point of Care (POC) COVID-19 Antigen Test Market size was valued at USD 11.01 billion in 2026 and is expected to decline at a CAGR of -7.8% from 2026 to 2033, reaching approximately 4.98 billion by 2033.
The Global Rapid Point of Care (POC) COVID-19 Antigen Test Market refers to the worldwide industry involved in the development, manufacturing, distribution, and use of rapid diagnostic kits that detect SARS-CoV-2 antigens at or near patient locations. These tests deliver results within 15–30 minutes without requiring centralized laboratories, enabling immediate clinical or personal decision-making. The market encompasses test kits, reagents, platforms, and associated services used across hospitals, clinics, workplaces, and home settings. It is driven by the need for fast, cost-effective, and scalable testing solutions to manage infectious disease spread and support public health surveillance systems globally.
Rapid Point Of Care COVID-19 Antigen Test Market Latest Trends
Key trends shaping the market include the rapid shift toward decentralized diagnostics and self-testing solutions, with home-based antigen kits gaining strong adoption. Increasing regulatory approvals and emergency authorizations have accelerated product innovation and commercialization. Integration of digital tools and mobile applications for result tracking is also emerging. Additionally, widespread use in workplaces, schools, and travel screening has expanded demand beyond clinical settings. Technological improvements in lateral flow assays and immunoassay platforms enhance sensitivity and usability. The broader trend toward point-of-care healthcare delivery, combined with affordability and convenience, continues to reinforce market penetration across both developed and emerging regions.
Segmentation: The Global Rapid Point of Care COVID-19 Antigen Test Market is segmented by Product Type (Over-the-Counter (OTC) Tests and Prescription-Based Tests), Product (Reagents & Kits, Platforms and Services), Application (Hospitals & Clinics, Diagnostic Laboratories / Centers, Home Care Settings and Others), Technology (Lateral Flow Immunoassays (LFAs), Immunoassay-Based Techniques and Other Emerging Technologies), Distribution Channel (Retail Pharmacies & Online Channels, Hospitals & Institutional Procurement and Government Supply Programs), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report provides the value (in USD million) for the above segments.
Market Drivers:
- Need for rapid and timely diagnosis to control infectious disease spread
A primary driver is the need for rapid and timely diagnosis to control infectious disease spread. COVID-19 highlighted the importance of immediate test results for isolating infected individuals and preventing transmission. Rapid antigen tests provide results within minutes, enabling real-time decision-making in hospitals, workplaces, and public settings. This capability supports mass screening programs and reduces pressure on laboratory infrastructure. Governments and health organizations have widely adopted these tests for surveillance and containment strategies. The ability to conduct frequent, large-scale testing efficiently has significantly boosted demand, making rapid POC antigen testing a critical tool in global pandemic response frameworks.
- Increasing adoption of decentralized and home-based healthcare solutions
Another key driver is the increasing adoption of decentralized and home-based healthcare solutions. Consumers and healthcare systems are shifting toward convenient, accessible diagnostics that reduce dependency on centralized laboratories. Rapid antigen self-test kits align with this trend by allowing individuals to test themselves at home quickly and safely. This reduces hospital visits, lowers infection risk, and enhances patient autonomy. Additionally, government initiatives promoting self-testing and public awareness campaigns have accelerated uptake. The broader movement toward point-of-care diagnostics, supported by technological advancements and retail distribution channels, continues to expand the market’s reach and sustain long-term growth.
Market Restraints:
- Relatively lower sensitivity and accuracy of rapid antigen tests
A major restraint is the relatively lower sensitivity and accuracy of rapid antigen tests compared to molecular PCR tests. False negatives, especially in early or asymptomatic infections, can limit clinical reliability and reduce confidence among healthcare professionals. Regulatory scrutiny and quality control requirements further challenge manufacturers, potentially delaying product approvals. Additionally, declining COVID-19 case numbers and reduced emergency demand are leading to market contraction in some regions. Concerns over test performance variability in home settings also hinder adoption. These limitations restrict the use of antigen tests in critical diagnostic scenarios and may impact long-term market sustainability despite their convenience and speed advantages.
Socioeconomic Impact on Rapid Point Of Care COVID-19 Antigen Test Market
The market has had a profound socioeconomic impact by enabling large-scale, affordable testing and supporting economic reopening during the pandemic. Rapid antigen tests reduce diagnostic turnaround time, helping governments and organizations manage outbreaks efficiently and maintain workforce continuity. Their lower cost compared to PCR testing allows wider accessibility, particularly in low-resource settings, improving health equity. Frequent screening in schools, workplaces, and travel sectors has minimized disruptions to economic activity. Moreover, home-testing options empower individuals to monitor health independently, reducing healthcare burden. Overall, the market contributes to public health resilience, economic stability, and improved pandemic preparedness across global healthcare systems.
Segmental Analysis:
- Over-the-Counter (OTC) Tests segment is expected to witness highest growth over the forecast period
The Over-the-Counter (OTC) tests segment is expected to witness the highest growth over the forecast period due to increasing consumer preference for convenient, at-home diagnostic solutions. These tests eliminate the need for clinical visits, offering rapid results and enhancing accessibility, particularly in remote or resource-limited areas. Government approvals and public health initiatives promoting self-testing have further accelerated adoption. Rising awareness about early detection and infection control also contributes to demand. Additionally, the expansion of e-commerce and retail pharmacy networks has made OTC kits widely available. Continuous improvements in usability, affordability, and accuracy are expected to sustain strong growth in this segment globally.
- Reagents & Kits segment is expected to witness highest growth over the forecast period
The reagents and kits segment is anticipated to experience the highest growth due to its central role in enabling rapid antigen testing. These consumables are required for every test conducted, leading to recurring demand across healthcare and home settings. The widespread use of lateral flow assays and increasing frequency of testing in workplaces, travel, and public health programs are key growth drivers. Additionally, manufacturers are focusing on improving sensitivity and shelf life, enhancing product reliability. Bulk procurement by governments and institutions further supports volume expansion. As testing becomes more routine and decentralized, the demand for cost-effective and easy-to-use reagents and kits is expected to rise significantly.
- Hospitals & Clinics segment is expected to witness highest growth over the forecast period
The hospitals and clinics segment is projected to witness the highest growth owing to the continued need for professional diagnostic services and patient management. These settings serve as primary points for testing symptomatic individuals and high-risk populations. Rapid antigen tests enable quick triage and treatment decisions, improving patient flow and reducing burden on laboratory infrastructure. Increasing patient footfall, coupled with ongoing infection surveillance protocols, supports sustained demand. Healthcare providers also prefer reliable and regulated testing solutions, further boosting adoption in clinical environments. Integration of rapid testing into routine diagnostic workflows and emergency care is expected to drive significant growth in this segment over time.
- Lateral Flow Immunoassays (LFAs) segment is expected to witness highest growth over the forecast period
The lateral flow immunoassays (LFAs) segment is expected to register the highest growth due to its simplicity, speed, and cost-effectiveness. LFAs form the backbone of most rapid antigen tests, providing results within minutes without requiring specialized equipment or trained personnel. Their ease of use makes them ideal for both professional and home settings. Continuous technological advancements have improved sensitivity and specificity, addressing earlier limitations. The scalability of LFA production enables manufacturers to meet large-scale testing demands during outbreaks. Additionally, their adaptability for detecting multiple pathogens supports long-term utility. These advantages position LFAs as the preferred technology, driving robust expansion in the global market.
- Retail Pharmacies & Online Channels segment is expected to witness highest growth over the forecast period
The retail pharmacies and online channels segment is expected to witness the highest growth as distribution models shift toward consumer-centric accessibility. Retail pharmacies provide trusted, convenient points of purchase, while online platforms offer discreet and doorstep delivery options. The surge in e-commerce adoption has significantly expanded market reach, especially during and after the pandemic. Promotional campaigns and government-backed distribution programs further enhance visibility and uptake. Online platforms also enable price comparisons and bulk purchasing, attracting cost-conscious consumers. As self-testing becomes normalized, these channels will play a critical role in ensuring consistent availability, thereby driving sustained growth and strengthening market penetration globally.
- North American region is expected to witness highest growth over the forecast period
The North American region is anticipated to witness the highest growth due to advanced healthcare infrastructure, high testing awareness, and strong government support.
The presence of leading diagnostic companies and rapid regulatory approvals has facilitated early adoption of innovative testing solutions. Widespread use of self-testing kits and workplace screening programs further drives demand. For instance, in July 2025, Becton, Dickinson and Company received U.S. Food and Drug Administration 510(k) clearance for its BD Veritor System for SARS-CoV-2, which strengthened the Global Rapid Point of Care COVID-19 Antigen Test Market by accelerating adoption of rapid, digital diagnostics. It improved testing efficiency, expanded access across decentralized care settings, and reinforced confidence in antigen-based testing solutions worldwide.
Additionally, robust reimbursement policies and public health initiatives promote frequent testing across various population groups. The region also benefits from high healthcare expenditure and technological advancements in diagnostics. Continued focus on preparedness for future outbreaks and integration of rapid testing into routine healthcare practices are expected to sustain growth in North America.
Rapid Point Of Care COVID-19 Antigen Test Market Competitive Landscape
The competitive landscape is moderately consolidated, with global diagnostics companies dominating alongside emerging regional manufacturers. Key players compete on product accuracy, speed, pricing, and regulatory approvals such as Emergency Use Authorizations. Strategic initiatives include new product launches, partnerships with governments, and geographic expansion. Innovation in rapid testing formats and digital integration further differentiates competitors. Asia-Pacific has seen strong participation from local firms, increasing competition globally. Companies also focus on scaling production capacity to meet fluctuating demand. Overall, the market is characterized by intense competition, rapid technological advancements, and continuous efforts to enhance test performance and accessibility.
The major players are:
- Abbott
- SD Biosensor Inc.
- Mylab Discovery Solutions Pvt. Ltd.
- GenBody Inc.
- F. Hoffmann-La Roche AG
- Access Bio, Inc.
- ADS Biotech Inc.
- PerkinElmer, Inc.
- Princeton BioMeditech Corporation
- Becton, Dickinson and Company
- Quidel Corporation
- Laboratory Corporation of America
- Siemens Healthineers
- BioMérieux SA
- Danaher Corporation
- OraSure Technologies
- Chembio Diagnostics Systems Inc.
- EKF Diagnostics
- Nova Biomedical
Recent Development
- In October 2025, an article published in the journal Scientific Reports, by researchers of Ain Shams University, Cairo, Egypt, stated that reagent-free COVID-19 detection using miniaturized MEMS-based FTIR spectrometers combined with machine learning. It analyzed nasopharyngeal samples with NIR and MIR systems, achieving up to 80% accuracy and high sensitivity within minutes. This innovation strengthened the Global Rapid Point of Care COVID-19 Antigen Test Market by advancing faster, non-invasive diagnostic technologies.
- In September 2025, QuidelOrtho Corporation expanded its QUICKVUE portfolio with a multiplex rapid test, which strengthened the Global Rapid Point of Care COVID-19 Antigen Test Market. The innovation enhanced diagnostic efficiency by enabling simultaneous detection of multiple respiratory infections, improved clinical decision-making, and increased demand for advanced, multi-analyte point-of-care testing solutions globally.
Frequently Asked Questions (FAQ) :
Q1. What are the main growth-driving factors for this market?
The market is primarily driven by the shift toward decentralized and home-based testing as a permanent fixture of public health. Key catalysts include the integration of tests into digital health apps, the demand for affordable mass screening in workplaces and travel, and the rising adoption of multiplex assays that detect COVID-19 alongside Influenza and RSV from a single sample.
Q2. What are the main restraining factors for this market?
Growth is hindered by declining perceived urgency compared to the peak pandemic years and the inherent accuracy limitations of antigen tests versus PCR. Significant barriers also include the environmental impact of single-use plastic waste, variable regulatory validation for new variants, and the technical challenge of maintaining test sensitivity as the virus continues to evolve.
Q3. Which segment is expected to witness high growth?
The Over-the-Counter (OTC) tests segment is expected to witness the highest growth due to rising demand for convenient, home-based diagnostics. Easy accessibility, rapid results, and increasing consumer awareness drive adoption. Expanding retail and online availability, along with supportive regulations and improved affordability, further accelerates growth across both developed and emerging markets.
Q4. Who are the top major players for this market?
The market is led by global diagnostics giants and established medical technology firms: • Abbott Laboratories (BinaxNOW/Panbio) • F. Hoffmann-La Roche Ltd. • Becton, Dickinson and Company (BD) • QuidelOrtho Corporation • Siemens Healthineers • Danaher Corporation (Cepheid) • Healgen Scientific LLC • SD Biosensor, Inc.
Q5. Which country is the largest player?
The United States is the largest player in the market, holding over 40% of the global revenue share. This dominance is fuelled by a robust retail pharmacy testing network and a mature reimbursement landscape for POC diagnostics. However, India and China are the fastest-expanding markets due to their massive populations and government-led primary healthcare infrastructure improvements.
List of Figures
Figure 1: Global Rapid Point Of Care COVID-19 Antigen Test Market Revenue Breakdown (USD Billion, %) by Region, 2022 & 2029
Figure 2: Global Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 1, 2022 & 2029
Figure 3: Global Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 4: Global Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 5: Global Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 2, 2022 & 2029
Figure 6: Global Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 7: Global Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 8: Global Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 9: Global Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Others, 2018-2029
Figure 10: Global Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 3, 2022 & 2029
Figure 11: Global Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 12: Global Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 13: Global Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 14: Global Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Others, 2018-2029
Figure 15: Global Rapid Point Of Care COVID-19 Antigen Test Market Value (USD Billion), by Region, 2022 & 2029
Figure 16: North America Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 1, 2022 & 2029
Figure 17: North America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 18: North America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 19: North America Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 2, 2022 & 2029
Figure 20: North America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 21: North America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 22: North America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 23: North America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Others, 2018-2029
Figure 24: North America Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 3, 2022 & 2029
Figure 25: North America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 26: North America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 27: North America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 28: North America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Others, 2018-2029
Figure 29: North America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by U.S., 2018-2029
Figure 30: North America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Canada, 2018-2029
Figure 31: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 1, 2022 & 2029
Figure 32: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 33: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 34: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 2, 2022 & 2029
Figure 35: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 36: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 37: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 38: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Others, 2018-2029
Figure 39: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 3, 2022 & 2029
Figure 40: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 41: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 42: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 43: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Others, 2018-2029
Figure 44: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Brazil, 2018-2029
Figure 45: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Mexico, 2018-2029
Figure 46: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Rest of Latin America, 2018-2029
Figure 47: Europe Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 1, 2022 & 2029
Figure 48: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 49: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 50: Europe Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 2, 2022 & 2029
Figure 51: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 52: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 53: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 54: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Others, 2018-2029
Figure 55: Europe Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 3, 2022 & 2029
Figure 56: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 57: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 58: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 59: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Others, 2018-2029
Figure 60: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by U.K., 2018-2029
Figure 61: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Germany, 2018-2029
Figure 62: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by France, 2018-2029
Figure 63: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Italy, 2018-2029
Figure 64: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Spain, 2018-2029
Figure 65: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Russia, 2018-2029
Figure 66: Europe Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Rest of Europe, 2018-2029
Figure 67: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 1, 2022 & 2029
Figure 68: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 69: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 70: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 2, 2022 & 2029
Figure 71: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 72: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 73: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 74: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Others, 2018-2029
Figure 75: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 3, 2022 & 2029
Figure 76: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 77: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 78: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 79: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Others, 2018-2029
Figure 80: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by China, 2018-2029
Figure 81: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by India, 2018-2029
Figure 82: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Japan, 2018-2029
Figure 83: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Australia, 2018-2029
Figure 84: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Southeast Asia, 2018-2029
Figure 85: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Rest of Asia Pacific, 2018-2029
Figure 86: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 1, 2022 & 2029
Figure 87: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 88: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 89: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 2, 2022 & 2029
Figure 90: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 91: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 92: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 93: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Others, 2018-2029
Figure 94: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Value Share (%), By Segment 3, 2022 & 2029
Figure 95: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 96: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 97: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 98: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Others, 2018-2029
Figure 99: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by GCC, 2018-2029
Figure 100: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by South Africa, 2018-2029
Figure 101: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Forecast (USD Billion), by Rest of Middle East & Africa, 2018-2029
List of Tables
Table 1: Global Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 2: Global Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 3: Global Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 4: Global Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Region, 2018-2029
Table 5: North America Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 6: North America Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 7: North America Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 8: North America Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Table 9: Europe Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 10: Europe Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 11: Europe Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 12: Europe Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Table 13: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 14: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 15: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 16: Latin America Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Table 17: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 18: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 19: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 20: Asia Pacific Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Table 21: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 22: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 23: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 24: Middle East & Africa Rapid Point Of Care COVID-19 Antigen Test Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Research Process
Data Library Research are conducted by industry experts who offer insight on
industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager
and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
![research-methodology1]()
Primary Research
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary Research
Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size Estimation
Both, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
![research-methodology2]()
